[go: up one dir, main page]

AR025609A1 - Formulaciones lipidas solidas - Google Patents

Formulaciones lipidas solidas

Info

Publication number
AR025609A1
AR025609A1 ARP000104722A ARP000104722A AR025609A1 AR 025609 A1 AR025609 A1 AR 025609A1 AR P000104722 A ARP000104722 A AR P000104722A AR P000104722 A ARP000104722 A AR P000104722A AR 025609 A1 AR025609 A1 AR 025609A1
Authority
AR
Argentina
Prior art keywords
solid lipid
lipid formulations
fatty acid
acid ester
depoliol
Prior art date
Application number
ARP000104722A
Other languages
English (en)
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8238989&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR025609(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of AR025609A1 publication Critical patent/AR025609A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0007—Effervescent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Obesity (AREA)
  • Physiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

El presente invento se refiere a una composicion farmacéutica que comprende por lo menos un inhibidor de lipasas y por lo menos un éster de ácido graso depolioles, caracterizado porque el éster de ácido graso tiene un punto de fusion por encima de latemperatura corporal y los polioles se eligen del grupoconstituido por azucares, derivados de azucar y sus mezclas.
ARP000104722A 1999-09-13 2000-09-08 Formulaciones lipidas solidas AR025609A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP99118179 1999-09-13

Publications (1)

Publication Number Publication Date
AR025609A1 true AR025609A1 (es) 2002-12-04

Family

ID=8238989

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP000104722A AR025609A1 (es) 1999-09-13 2000-09-08 Formulaciones lipidas solidas

Country Status (36)

Country Link
US (1) US6703369B1 (es)
EP (1) EP1216048B1 (es)
JP (1) JP4217017B2 (es)
KR (1) KR100523879B1 (es)
CN (1) CN1197554C (es)
AR (1) AR025609A1 (es)
AT (1) ATE285783T1 (es)
AU (1) AU769016B2 (es)
BR (1) BRPI0013940B1 (es)
CA (1) CA2383036C (es)
CO (1) CO5210857A1 (es)
CZ (1) CZ301844B6 (es)
DE (1) DE60017156T2 (es)
EG (1) EG24225A (es)
ES (1) ES2233444T3 (es)
GC (1) GC0000259A (es)
HK (1) HK1049798B (es)
HR (1) HRP20020206B1 (es)
HU (1) HU229037B1 (es)
IL (2) IL148570A0 (es)
JO (1) JO2300B1 (es)
MA (1) MA26817A1 (es)
ME (1) MEP90908A (es)
MX (1) MXPA02002662A (es)
MY (1) MY127430A (es)
NO (1) NO328889B1 (es)
NZ (1) NZ517396A (es)
PE (1) PE20010661A1 (es)
PL (1) PL199869B1 (es)
PT (1) PT1216048E (es)
RS (1) RS50373B (es)
RU (1) RU2248218C2 (es)
SI (1) SI1216048T1 (es)
TR (1) TR200200605T2 (es)
WO (1) WO2001019378A2 (es)
ZA (1) ZA200201249B (es)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011091816A1 (en) 2010-02-01 2011-08-04 Laboratorios Bagó S.A. Pharmaceutical composition with anti-obesity activity comprising a premixture of pure orlistat and preparation process

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR025609A1 (es) * 1999-09-13 2002-12-04 Hoffmann La Roche Formulaciones lipidas solidas
HRP20030029B1 (en) * 2000-07-28 2005-06-30 F. Hoffmann - La Roche Ag New pharmaceutical composition
US6730319B2 (en) * 2001-06-06 2004-05-04 Hoffmann-La Roche Inc. Pharmaceutical compositions having depressed melting points
US20030027786A1 (en) * 2001-06-06 2003-02-06 Karsten Maeder Lipase inhibiting composition
DE10251963A1 (de) * 2002-11-08 2004-05-19 Lts Lohmann Therapie-Systeme Ag Transmucosale pharmazeutische Darreichungsform
US8372430B2 (en) * 2002-12-17 2013-02-12 The Procter & Gamble Company Compositions, methods, and kits useful for the alleviation of gastrointestinal effects
CA2518442A1 (en) * 2003-03-04 2004-09-16 Nostrum Pharmaceuticals, Inc. Control release formulation containing a hydrophobic material as the sustained release agent
FI20045076A7 (fi) * 2004-03-15 2005-09-16 Bioferme Oy Funktionaalinen elintarvike
AU2005297923B2 (en) * 2004-10-25 2010-12-23 Japan Tobacco Inc. Solid medicinal preparation improved in solubility and stability and process for producing the same
KR100669497B1 (ko) * 2005-08-17 2007-01-16 보람제약주식회사 안정성과 용출률이 뛰어난 약리학적 조성물 및 그 제조방법
WO2007073389A1 (en) * 2005-12-22 2007-06-28 Teva Pharmaceutical Industries Ltd. Compressed solid dosage forms with drugs of low solubility and process for making the same
EP1808163A1 (en) * 2005-12-22 2007-07-18 Teva Pharmaceutical Industries Ltd. Compressed solid dosage forms with drugs of low solubility and process for making the same
US20070148245A1 (en) * 2005-12-22 2007-06-28 Ilan Zalit Compressed solid dosage forms with drugs of low solubility and process for making the same
KR101252635B1 (ko) 2006-04-20 2013-04-10 (주)아모레퍼시픽 리파아제 저해제 및 친유성 오일흡수제를 포함하는 약학조성물 및 이로부터 제조된 경구 투여용 제제
KR100903504B1 (ko) * 2007-05-18 2009-06-17 강태용 비라칸사스 열매 추출물질을 포함하는 기능식품 및 체중 감소제
CA2697150A1 (en) * 2007-08-17 2009-02-26 Teva Pharmaceutical Industries Ltd. Methods and compositions for controlling the bioavailability of poorly soluble drugs
EP2036575B1 (en) * 2007-09-12 2010-08-18 Mader S.r.l. Pharmaceutical compositions for oral use for treating patients affected by obesity
PL216542B1 (pl) 2008-03-20 2014-04-30 Zakłady Farmaceutyczne POLPHARMA Spółka Akcyjna Sposób wytwarzania stabilnej kompozycji orlistatu w postaci kapsułkowanego proszku
WO2010042499A1 (en) * 2008-10-06 2010-04-15 Banner Pharmacaps, Inc. Stable solutions of orlistat for pharmaceutical dosage forms
BRPI0901602B8 (pt) 2009-04-03 2021-05-25 Ems S/A formulação farmacêuticas
EP2486805A1 (en) * 2011-02-11 2012-08-15 Puratos N.V. An emulsion whippable at room-temperature
WO2012140937A1 (ja) * 2011-04-14 2012-10-18 株式会社Ｊ－オイルミルズ パーム系分別油脂、それを配合した油脂組成物及び食品
CN102552168B (zh) * 2012-01-31 2013-08-07 杭州华东医药集团生物工程研究所有限公司 一种含有奥利司他的药物组合物及其制备方法
GB2501535A (en) 2012-04-26 2013-10-30 Sony Corp Chrominance Processing in High Efficiency Video Codecs
SG11201407397WA (en) * 2012-05-31 2014-12-30 Repros Therapeutics Inc Formulations and methods for vaginal delivery of antiprogestins
CA2923838A1 (en) * 2013-10-28 2015-05-07 Nestec S.A. Monoacylglycerols for use in conjunction with a lipase inhibitor and/or diets low in fat and/or calories
CN115105476B (zh) * 2021-03-23 2023-11-14 山东新时代药业有限公司 一种奥利司他冻干口服制剂及其制备工艺

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1247547A (en) * 1983-06-22 1988-12-28 Paul Hadvary Leucine derivatives
FR2710264B1 (fr) * 1993-09-21 1995-12-08 Rocher Yves Biolog Vegetale Utilisation pour le traitement des peaux mixtes d'une quantité efficace de substances actives.
WO1998024607A1 (en) * 1996-12-04 1998-06-11 Pincott James S Process and apparatus for making crumb rubber from scrap tyres
US6004996A (en) * 1997-02-05 1999-12-21 Hoffman-La Roche Inc. Tetrahydrolipstatin containing compositions
NZ336755A (en) 1997-02-05 2001-06-29 F Use of gastrointestinal lipase inhibitors in particular tetrahydrolipstatin (orlistat)
US6267952B1 (en) 1998-01-09 2001-07-31 Geltex Pharmaceuticals, Inc. Lipase inhibiting polymers
CN1170534C (zh) 1998-08-14 2004-10-13 霍夫曼-拉罗奇有限公司 含有脂酶抑制剂的药物组合物
JP3761783B2 (ja) * 1998-08-14 2006-03-29 エフ．ホフマン−ラ ロシュ アーゲー リパーゼ阻害剤とキトサンを含む製薬学的組成物
AR025609A1 (es) * 1999-09-13 2002-12-04 Hoffmann La Roche Formulaciones lipidas solidas

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011091816A1 (en) 2010-02-01 2011-08-04 Laboratorios Bagó S.A. Pharmaceutical composition with anti-obesity activity comprising a premixture of pure orlistat and preparation process

Also Published As

Publication number Publication date
IL148570A (en) 2007-03-08
AU769016B2 (en) 2004-01-15
JP2003509373A (ja) 2003-03-11
BR0013940A (pt) 2002-05-14
ME00675B (me) 2011-12-20
CN1373659A (zh) 2002-10-09
HRP20020206B1 (en) 2011-02-28
TR200200605T2 (tr) 2002-08-21
HU229037B1 (en) 2013-07-29
HK1049798B (zh) 2005-08-05
ES2233444T3 (es) 2005-06-16
CZ301844B6 (cs) 2010-07-07
IL148570A0 (en) 2002-09-12
PL356154A1 (en) 2004-06-14
RU2248218C2 (ru) 2005-03-20
KR100523879B1 (ko) 2005-10-26
CN1197554C (zh) 2005-04-20
JP4217017B2 (ja) 2009-01-28
GC0000259A (en) 2006-11-01
YU13602A (sh) 2006-01-16
SI1216048T1 (en) 2005-06-30
ATE285783T1 (de) 2005-01-15
HK1049798A1 (en) 2003-05-30
BRPI0013940B1 (pt) 2016-06-21
NO20021205D0 (no) 2002-03-12
MY127430A (en) 2006-11-30
CA2383036A1 (en) 2001-03-22
CZ20021277A3 (cs) 2003-04-16
WO2001019378A3 (en) 2001-05-10
ZA200201249B (en) 2003-07-30
CO5210857A1 (es) 2002-10-30
AU7517700A (en) 2001-04-17
NO328889B1 (no) 2010-06-07
MA26817A1 (fr) 2004-12-20
HRP20020206A2 (en) 2004-04-30
NO20021205L (no) 2002-03-12
PE20010661A1 (es) 2001-06-25
CA2383036C (en) 2006-01-10
JO2300B1 (en) 2005-09-12
NZ517396A (en) 2003-10-31
KR20020060177A (ko) 2002-07-16
DE60017156T2 (de) 2006-01-05
RS50373B (sr) 2009-11-10
US6703369B1 (en) 2004-03-09
EP1216048B1 (en) 2004-12-29
MXPA02002662A (es) 2002-07-30
PT1216048E (pt) 2005-04-29
EG24225A (en) 2008-11-10
HUP0202762A3 (en) 2005-04-28
RU2002107450A (ru) 2004-01-10
HUP0202762A2 (hu) 2003-01-28
WO2001019378A2 (en) 2001-03-22
DE60017156D1 (de) 2005-02-03
MEP90908A (en) 2011-12-20
PL199869B1 (pl) 2008-11-28
EP1216048A2 (en) 2002-06-26

Similar Documents

Publication Publication Date Title
AR025609A1 (es) Formulaciones lipidas solidas
PL346149A1 (en) Amphoteric derivatives of aliphatic polyamines with fatty acids, esters or triglycerides
ES2052645T3 (es) Acidos poliinsaturados con accion vasocinetica y formulaciones farmaceuticas y cosmeticas que los contienen.
ES2195798T1 (es) Formulacion para mujeres menopausicas.
GT200200105A (es) Nueva composicion farmaceutica
HN2000000224A (es) Aminoacidos biciclicos como agentes farmaceuticos
AR034691A1 (es) Composiciones farmaceuticas de administracion oral, que contiene un inhibidor de lipasa gastrointestinal, el comprimido masticable y la galleta que los comprende
ATE478129T1 (de) Kerzenwachs auf triacylglycerin-basis
NZ516101A (en) Pharmaceutical and nutritional compositions containing essential fatty acids and homocysteine-lowering agents
CO4940469A1 (es) Composicion oral de estabilidad mejorada que comprende un derivado de indolinona y una mezcla de gliceridos o esteres de polietilenglicol
TNSN05189A1 (en) Medium-chain length fatty acids, glycerides and analogues as stimulators of erythropoiesis
ES2191862T3 (es) Composicion liquida que comprende un inhibidor de la vih proteasa y un acido graso de c12-c18.
UY26338A1 (es) Formulaciones dispersables conteniendo inhibidores de la lipasa
UY26303A1 (es) Composiciones farmacéuticas para administración oral y tópica
ES2149424T3 (es) Composicion de chocolate.
DK1608346T3 (da) Lægemiddeltilförselssammensætninger af alfa-hydroxysyreester og fremgangsmåder til anvendelse heraf
AR034355A1 (es) Nueva composicion farmaceutica
AR021934A1 (es) Composicion de administracion oral con liberacion controlada de al menos un analgesico
NO20024237D0 (no) Farmasöytiske formuleringer
DE69622706D1 (de) Durchscheinende kollagenformulierungen
AR016629A1 (es) Una solucion que comprende un azaesteroide farmaceuticamente activo y un ester de acido graso de glicerol o propilen glicol, composiciones farmaceuticasque comprenden la solucion y capsulas de gelatina rellenas con la composicion farmaceutica.
WO2002049582A3 (de) Kosmetische und dermatologische lichtschutzformulierungen mit einem gehalt an benzotriazolderivaten und oberflächenaktiven zitronensäureestern
ECSP003653A (es) Formulaciones solidas de lipido
UY26337A1 (es) Formulaciones de lipidos solidos
CA2556520A1 (en) Chromium-fatty acid compounds and methods of making and using thereof

Legal Events

Date Code Title Description
FC Refusal
FG Grant, registration